96 related articles for article (PubMed ID: 22067408)
1. Esophageal cancer: a critical evaluation of systemic second-line therapy.
Thallinger CM; Raderer M; Hejna M
J Clin Oncol; 2011 Dec; 29(35):4709-14. PubMed ID: 22067408
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy for recurrent and metastatic esophageal cancer.
Grünberger B; Raderer M; Schmidinger M; Hejna M
Anticancer Res; 2007; 27(4C):2705-14. PubMed ID: 17695436
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
4. Second-line therapy for esophageal cancer.
Martin MG; Govindan R; Morgensztern D
Expert Rev Anticancer Ther; 2007 Jun; 7(6):871-6. PubMed ID: 17555397
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
8. Nonsurgical management of malignant thymoma.
Hejna M; Haberl I; Raderer M
Cancer; 1999 May; 85(9):1871-84. PubMed ID: 10223225
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in esophageal cancer.
Enzinger PC; Ilson DH; Kelsen DP
Semin Oncol; 1999 Oct; 26(5 Suppl 15):12-20. PubMed ID: 10566606
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
12. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
13. Optimal treatment for localized esophageal cancer still uncertain.
Lord RV
Am J Gastroenterol; 2000 Jan; 95(1):305-7. PubMed ID: 10638607
[TBL] [Abstract][Full Text] [Related]
14. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
15. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy and multimodality therapy in the treatment of esophageal cancer].
Ando N; Ozawa S; Kitajima M; Iizuka T
Gan To Kagaku Ryoho; 1995 Jun; 22(7):869-76. PubMed ID: 7540823
[TBL] [Abstract][Full Text] [Related]
17. Esophageal cancer subtypes and survival rates at the VA Caribbean Healthcare System: a 10-year experience.
González Ortiz DI; Toro DH
Bol Asoc Med P R; 2009; 101(3):14-7. PubMed ID: 20120980
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
19. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015.
Castro C; Bosetti C; Malvezzi M; Bertuccio P; Levi F; Negri E; La Vecchia C; Lunet N
Ann Oncol; 2014 Jan; 25(1):283-90. PubMed ID: 24356640
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
